[go: up one dir, main page]

AU4690596A - Nucleic acid condensing agents with reduced immunogenicity - Google Patents

Nucleic acid condensing agents with reduced immunogenicity

Info

Publication number
AU4690596A
AU4690596A AU46905/96A AU4690596A AU4690596A AU 4690596 A AU4690596 A AU 4690596A AU 46905/96 A AU46905/96 A AU 46905/96A AU 4690596 A AU4690596 A AU 4690596A AU 4690596 A AU4690596 A AU 4690596A
Authority
AU
Australia
Prior art keywords
nucleic acid
reduced immunogenicity
condensing agents
acid condensing
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU46905/96A
Inventor
Nicholas J Depolo
David Chi-Tang Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Publication of AU4690596A publication Critical patent/AU4690596A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU46905/96A 1994-12-30 1995-12-26 Nucleic acid condensing agents with reduced immunogenicity Withdrawn AU4690596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36678794A 1994-12-30 1994-12-30
US366787 1994-12-30
PCT/US1995/017005 WO1996021036A2 (en) 1994-12-30 1995-12-26 Nucleic acid condensing agents with reduced immunogenicity

Publications (1)

Publication Number Publication Date
AU4690596A true AU4690596A (en) 1996-07-24

Family

ID=23444497

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46905/96A Withdrawn AU4690596A (en) 1994-12-30 1995-12-26 Nucleic acid condensing agents with reduced immunogenicity

Country Status (2)

Country Link
AU (1) AU4690596A (en)
WO (1) WO1996021036A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7001764B2 (en) * 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
ATE340259T1 (en) * 1996-07-16 2006-10-15 Archibald James Mixson CATIONIC VEHICLE: DNA COMPLEXES AND THEIR USE IN GENE THERAPY
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
DE19649645A1 (en) * 1996-11-29 1998-06-04 Hoechst Ag Multiple functional ligand system for target cell-specific transfer of nucleotide sequences
EP1905837A1 (en) * 1997-03-03 2008-04-02 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
JP2002514074A (en) * 1997-03-03 2002-05-14 セル ジェネシス,インコーポレイティド Adenovirus vectors containing heterologous transcriptional regulatory elements and methods of using the same
AU745056B2 (en) * 1997-04-03 2002-03-07 Genzyme Corporation Polymer-modified viruses
US6569426B2 (en) 1997-04-03 2003-05-27 Genzyme Corporation Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
US6306993B1 (en) 1997-05-21 2001-10-23 The Board Of Trustees Of The Leland Stanford, Jr. University Method and composition for enhancing transport across biological membranes
DE19726186A1 (en) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
AU7987898A (en) * 1997-06-26 1999-01-19 Albany Medical College Antigenic modulation of viral particules
EP1002103B1 (en) 1997-08-04 2007-10-17 Cell Genesys, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
EP0963758A3 (en) * 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
ATE411049T1 (en) * 1998-05-20 2008-10-15 Expression Genetics Inc LACTOSE OR GALACTOSE-POLYETHYLENE GLYCOL-GRABTED POLY-L-LYSINE AS A GENE CARRIER
EP1108048A1 (en) * 1998-08-24 2001-06-20 Genzyme Corporation Cationic complexes of polymer-modified adenovirus
IL142704A0 (en) * 1998-12-03 2002-03-10 Aventis Pharma Sa Novel nucleic acid transferring agents, compositions containing them and uses
FR2786700B1 (en) * 1998-12-03 2002-12-06 Aventis Pharma Sa NOVEL NUCLEIC ACID TRANSFERS, COMPOSITIONS CONTAINING THEM, AND USES THEREOF
JP5025059B2 (en) * 1999-06-25 2012-09-12 クリステン プランク Formulation for introducing nucleic acid into cells
EP1063254A1 (en) * 1999-06-25 2000-12-27 Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung Copolymers for the transport of nucleic acids in the cell
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
DE10015906B4 (en) * 2000-03-30 2006-09-07 Ibfb Pharma Gmbh Directed gene transfer into Thy-1 positive cells
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
DE102014016901B4 (en) 2014-09-17 2021-08-12 Friedrich-Schiller-Universität Jena Process for the production of new dextran derivatives as active ingredient carrier systems and their use
CN108350491A (en) 2015-11-18 2018-07-31 加利福尼亚太平洋生物科学股份有限公司 Nucleic acid is loaded on base material
CA3046680A1 (en) 2016-12-19 2018-06-28 Quantum-Si Incorporated Loading molecules into sample wells for analysis
EP3619323A4 (en) 2017-05-05 2021-01-27 Quantum-si Incorporated SUBSTRATES WITH MODIFIED SURFACE REACTIVITY AND AGING-INHIBITIVE PROPERTIES IN BIOLOGICAL REACTIONS
AU2019205383B8 (en) 2018-01-08 2023-09-28 Quantum-Si Incorporated System and methods for electrokinetic loading of sub-micron-scale reaction chambers
KR20220079943A (en) 2019-10-11 2022-06-14 퀀텀-에스아이 인코포레이티드 Surface modification in vapor phase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2122325A2 (en) * 1971-01-20 1972-09-01 Maes Roland Polynucleic acid/polycationic compounds - for potentiating antiviral vaccines
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
AU8628291A (en) * 1990-09-25 1992-04-15 University Of Connecticut, The Prolonging expression of polynucleotides introduced into a cell
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
ES2154637T3 (en) * 1991-05-14 2001-04-16 Univ Connecticut CONTRIBUTION OF DIRECT GENES THAT CODIFY IMMUNOGENIC PROTEINS.
AU681997B2 (en) * 1991-09-05 1997-09-18 University Of Connecticut, The Targeted delivery of poly- or oligonucleotides to cells
EP0693130A1 (en) * 1993-04-05 1996-01-24 The University Of Connecticut Targeted delivery of genes encoding antisense polyribonucleotides
DE4418965A1 (en) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Transfection of eukaryotic cells with nucleic acid

Also Published As

Publication number Publication date
WO1996021036A2 (en) 1996-07-11
WO1996021036A3 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
AU4690596A (en) Nucleic acid condensing agents with reduced immunogenicity
DE69522690D1 (en) alpha-ketogultaric acid dehydrogenase gene
AU2757897A (en) Nucleic acid sensor
GB9626637D0 (en) Percarboxyilic acid solutions
AU6482398A (en) Sulfonylaminocarboxylic acids
AU2602297A (en) Thickened acid composition
AU2929495A (en) Nucleic acid sequence amplification method
AU6591798A (en) Nucleic acid catalysts
AU1889797A (en) Nucleic acid sequence detection
AU2623795A (en) Immunogenic pharmaceuticals
AU1559199A (en) Isothiazolcarboxylic acid derivatives
AU1364995A (en) 5-vinyl- and 5-ethinyl-quinolone- carboxylic acids
AU8234898A (en) Characterising nucleic acid
AU7813698A (en) Nucleic acid detection
AU5178999A (en) Nucleic acid delivery
AU5345798A (en) Fructan-polycarboxylic acid
AU5905094A (en) Nucleic acid assay procedure
AU6376698A (en) Improved nucleic acid assays
AU3004695A (en) Nucleic acid filters
AU2629295A (en) Trifluoromethylquinolinecarboxylic acid derivative
AU8234798A (en) Categorising nucleic acid
GB9410170D0 (en) Nucleic acid
AU5370696A (en) Egf-targeted nucleic acid delivery
AU5377599A (en) Nucleic acids
AU3031495A (en) Tee peg